Magnesium supplementation prevents experimental chronic cyclosporine a nephrotoxicity via renin-angiotensin system independent mechanism

Transplantation

Volumn 74, Issue 6, 2002, Pages 784-791

  Asai, Toshihiro ^a   Nakatani, Tatsuya ^a   Yamanaka, Shinya ^a   Tamada, Satoshi ^a   Kishimoto, Taketoshi ^a   Tashiro, Koichiro ^a   Nakao, Takafumi ^a   Okamura, Mikio ^a   Kim, Shokei ^a   Iwao, Hiroshi ^a   Miura, Katsuyuki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; CHEMOATTRACTANT; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MAGNESIUM; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GLOMERULUS FILTRATION; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; MACROPHAGE; MALE; MONOCYTE; MONONUCLEAR CELL; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM RESTRICTION;

EID: 0037183859     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200209270-00009     Document Type: Article

References (30)

1. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35 (2): 333.
2. Miura K, Nakatani T, Asai T, et al. Role of hypomagnesemia in chronic cyclosporine nephropathy. Transplantation 2002; 73 (2): 340.
3. Young BA, Burdmann EA, Johnson RJ, et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 1995; 48 (2): 439.
4. Rodriguez-Iturbe B, Pons H, Herrera-Acosta J, Johnson RJ. Role of immunocompetent cells in nonimmune renal diseases. Kidney Int 2001; 59 (5): 1626.
5. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-betal and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52 (3): 660.
6. Pichler RH, Franceschini N, Young BA, et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6 (4): 1186.
7. Burdmann EA, Andoh TF, Nast CC, et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995; 269: F491.
8. Kon V, Hunley TE, Fogo A. Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis: studies in chronic cyclosporine nephrotoxicity in rats. Transplantation 1995; 60 (1): 89.
9. Burdmann EA, Andoh TF, Lindsley J, Houghton DC, Bennett WM. Effects of oral magnesium supplementation on acute experimental cyclosporin nephrotoxicity. Nephrol Dial Transplant 1994; 9 (1): 16.
10. Yoshimura T, Takeya M, Takahashi K. Molecular cloning of rat monocyte chemoattractant protein-1 (MCP-1) and its expression in rat spleen cells and tumor cell lines. Biochem Biophys Res Commun 1991; 174 (2): 504.
11. Nagasaki T, Ishimura E, Shioi A, et al. Osteopontin gene expression and protein synthesis in cultured rat mesangial cells. Biochem Biophys Res Commun 1997; 233 (1): 81.
12. Clarke MF, Westin E, Schmidt D, et al. Transformation of NIH 3T3 cells by a human c-sis cDNA clone. Nature 1984; 308 (5958): 464.
13. Kaye M. Magnesium metabolism in the rat with chronic renal failure. J Lab Clin Med 1974; 84 (4): 536.
14. Morrissey JJ, Klahr S. Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol 1998; 274: F580.
15. Taal MW, Zandi-Nejad K, Weening B, et al. Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int 2000; 58 (4): 1664.
16. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A 1986; 83 (23): 8819.
17. Hudkins KL, Le QC, Segerer S, et al. Osteopontin expression in human cyclosporine toxicity. Kidney Int 2001; 60 (2): 635.
18. Bidani AK, Griffin KA, Bakris G, Picken MM. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int 2000; 57 (4): 1651.
19. Li J, Zhou C, Yu L, Wang H. Renal protective effects of blocking the intrarenal renin-angiotensin system. Hypertens Res 1999; 22 (3): 223.
20. Kovacs EJ. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today 1991; 12 (1): 17.
21. Zhong Z, Arteel GE, Connor HD, et al. Cyclosporin A increases hypoxia and free radical production in rat kidneys: prevention by dietary glycine. Am J Physiol 1998; 275: F595.
22. Persy VP, Verstrepen WA, Ysebaert DK, De Greef KE, De Broe ME. Differences in osteopontin up-regulation between proximal and distal tubules after renal ischemia/reperfusion. Kidney Int 1999; 56 (2): 601.
23. Ivacko J, Szaflarski J, Malinak C, Flory C, Warren JS, Silverstein FS. Hypoxic-ischemic injury induces monocyte chemoattractant protein-1 expression in neonatal rat brain. J Cereb Blood Flow Metab 1997; 17 (7): 759.
24. Shoskes DA. Effect of bioflavonoids quercetin and curcumin on ischemic renal injury: a new class of renoprotective agents. Transplantation 1998; 66 (2): 147.
25. Orphanides C, Fine LG, Norman JT. Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1-independent mechanism. Kidney Int 1997; 52 (3): 637.
26. Shehata M, el Nahas M, Barkworth E, Cope GH, Raftery AT. Localization of PDGF-BB in the juxtaglomerular cells of cyclosporin-treated rats. Exp Nephrol 1995; 3 (3): 173.
27. Basile DP, Martin DR, Hammerman MR. Extracellular matrix-related genes in kidney after ischemic injury: potential role for TGF-beta in repair. Am J Physiol 1998; 275: F894.
28. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000; 58 (6): 2351.
29. Kourembanas S, Marsden PA, McQuillan LP, Faller DV. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 1991; 88 (3): 1054.
30. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79 (4): 1283.